Assembly Biosciences (NASDAQ: ASMB) is a clinical-stage biotechnology company committed to bringing finite and curative therapies to the 270 million people living with hepatitis B virus (HBV) worldwide. A pioneer in the development of a new class of potent, oral core inhibitor drug candidates, Assembly Bio’s approach aims to break the complex viral replication cycle of HBV to free patients from a lifetime of therapy. Assembly Bio’s strategy toward cure includes a leading portfolio of more potent, next-generation core inhibitors, proof-of-concept combination studies and a research program focused on the discovery of novel HBV targets. 

Biotechnology

Assembly Biosciences

Jason Okazaki

Anuj Gaggar

Zhixin Z.

Suzette DeVito

Qi Huang

John O. Gunderson

Grace Wang

Gayan Bogollaga

Nicole S. White

William Delaney

Jennifer Troia

The board of directors at Assembly Biosciences has a history of experience in the financial side of various companies in the biotech industry. This is seen through previous experiences of members on the board, such as the Chief Financial Officer at Diversa and the Board of Directors at TearLab Corporation. Furthermore, the education histories of the members on the board indicate a strong financial background, with degrees in business from notable universities. Consequently, the financial decisions made by the board are likely to be well-informed and advantageous to Assembly Biosciences.

Board of Directors

Leadership Team

CEO and Executive Team

Board of Directors

About

Team members

Other teams at Assembly Biosciences

Leadership Team

CEO and Executive Team